Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Celebrity birthdays for the week of May 26
UMass Dartmouth's billionaire commencement speaker stuns graduates by giving them each $1,000
China's 10th National Public Ice and Snow Season launched
Fermín brace paves way as Barca beat Almería
Dodgers acquire pitcher Yohan Ramírez from Mets for cash
Mongolia suspends transfer of citizens due to parliamentary elections
Australia to host 2026 AFC Women's Asian Cup
Nighttime entertainment boom invigorates tourism, consumption in Lanzhou
With Djokovic awaiting the winner, Murray trails Hanfmann at rain
Nearly 30,000 Chinese tourists visit Sri Lanka
Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
Barcelona beat Real Sociedad to move second